Vepotolizumab (POLIVY) latest price in 2023

Vepotuzumab (POLIVY) is a drug targeting CD79b-positive diffuse large B-cell lymphoma (DLBCL). It belongs to antibody drug complexes (ADCs) and consists of three main components: a monoclonal antibody with anti-tumor activity, a linker and a cytotoxin. The monoclonal antibody in velpotuzumab selectively binds to CD79b-positive DLBCL cells and releases linker-mediated cytotoxicity into these cancer cells, resulting in cell death.

The mechanism of action of vepotuzumab is by bindingCD79b protein to deliver cytotoxins into cancer cells, thereby causing cancer cell death. This targeted therapy method for specific molecules has a more precise and specific mode of action than traditional chemotherapy, and can effectively inhibit the growth and spread of cancer cells. Vepotolizumab is not suitable for all patients with DLBCL, and treatment effects may vary depending on individual differences.

The patent drug Vepotuzumab has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. It is understood that the price of 30mg per box may be around 10,000 RMB, the Hong Kong version of 140mg may be priced around 60,000 RMB per box (the price may fluctuate due to the exchange rate), and the European version of vepotuzumab listed overseas, SpecificationsThe price of each box of 140 mg may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There is currently no generic version of vepotuzumab produced and launched.